Gilead Sciences Inc (NASDAQ:GILD)

103.70
Delayed Data
As of Apr 24
 -1.51 / -1.44%
Today’s Change
71.63
Today|||52-Week Range
116.83
+10.01%
Year-to-Date
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Apr 24 / Zacks.com
Double-Digit Spike in Drug Costs Prescribes Profits for PBMs
Apr 20 / MotleyFool.com
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Apr 24 / Zacks.com
Why This Trader Likes Gilead Better Than Biogen
Apr 19 / Benzinga
The Parade of Weak Earnings Reports Continues - Earnings Preview
Apr 24 / Zacks.com
How to Invest Money in Biotech
Apr 19 / MotleyFool.com
I'm Going to Keep Riding These Horses
Apr 24 / TheStreet.com
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Apr 19 / MotleyFool.com
4 Nasdaq Stocks at All-Time Highs - Analyst Blog
Apr 24 / Zacks.com
3 Drug Stocks Leading the Charge Against Infectious Diseases
Apr 18 / MotleyFool.com
Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog
Apr 23 / Zacks.com
What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Apr 18 / MotleyFool.com
Is Amgen Inc.'s Dividend Sustainable?
Apr 23 / MotleyFool.com
Revenue Weakness Stands Out in Q1 Earnings Season - Earnings Preview
Apr 17 / Zacks.com
5 Things UnitedHealth Wants You to Know
Apr 23 / MotleyFool.com
Megamergers rarely mean megabucks for shareholders
Apr 17 / FT.com
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampi...
Apr 22 / Zacks.com
AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
Apr 16 / Zacks.com
Gilead Sciences (GILD) Stock Is the 'Chart of the Day'
Apr 22 / TheStreet.com
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
Apr 16 / MotleyFool.com
Gilead May Be the Cure for the Blues
Apr 22 / TheStreet.com
Healthcare ETFs in Focus Post JNJ Earnings Beat - ETF News And Commentary
Apr 16 / Zacks.com
Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth'
Apr 22 / TheStreet.com
The Best Stock to Invest in Hep C
Apr 16 / MotleyFool.com
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson ...
Apr 22 / Zacks.com
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Apr 15 / Zacks.com
Gilead May Be the Cure for the Blues
Apr 22 / TheStreet.com
J&J cuts guidance as strong dollar hits sales
Apr 14 / FT.com
Benzinga's M&A Chatter for Tuesday April 21, 2015
Apr 21 / Benzinga
J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings ...
Apr 14 / Zacks.com
Gilead (GILD) Marked As A Barbarian At The Gate
Apr 21 / TheStreet.com
Q1 Earnings Season Ramps Up - Earnings Preview
Apr 13 / Zacks.com
Should Gilead Buy Vertex?
Apr 21 / Benzinga
Biotech: Making sense of the science
Apr 13 / FT.com
Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals
Apr 21 / Benzinga
3 Stocks You Absolutely Must Watch This Earnings Season
Apr 13 / MotleyFool.com
Gilead Is Poised to Go Higher
Apr 21 / TheStreet.com
Stock Market News for April 13, 2015 - Market News
Apr 13 / Zacks.com
Dow Extends Losses as Travelers Companies Misses Earnings Estimates
Apr 21 / TheStreet.com
Gilead combats wider distribution of cheap drugs from EM
Apr 12 / FT.com
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Apr 21 / Zacks.com
High price of gene therapy drug adds to costs debate
Apr 06 / FT.com
Gilled Should Buy Vertex Pharma for $45B Now, Analyst Says
Apr 21 / TheStreet.com
City accused of failing to back life sciences sector
Mar 29 / FT.com
Gilead Sciences, Inc. (GILD): The Stock To Own In 2015
Apr 20 / Investing Channel
 

To view my watchlist

Not a member yet?

Sign up now for a free account